Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Caspofungin is an echinocandin agent with fungicidal activity against candida species. We performed a double-blind trial to compare caspofungin with amphotericin B deoxycholate for the primary treatment of invasive candidiasis. METHODS: We enrolled patients who had clinical evidence of infection and a positive culture for candida species from blood or another site. Patients were stratified according to the severity of disease, as indicated by the Acute Physiology and Chronic Health Evaluation (APACHE II) score, and the presence or absence of neutropenia and were randomly assigned to receive either caspofungin or amphotericin B. The study was designed to compare the efficacy of caspofungin with that of amphotericin B in patients with invasive candidiasis and in a subgroup with candidemia. RESULTS: Of the 239 patients enrolled, 224 were included in the modified intention-to-treat analysis. Base-line characteristics, including the percentage of patients with neutropenia and the mean APACHE II score, were similar in the two treatment groups. A modified intention-to-treat analysis showed that the efficacy of caspofungin was similar to that of amphotericin B, with successful outcomes in 73.4 percent of the patients treated with caspofungin and in 61.7 percent of those treated with amphotericin B (difference after adjustment for APACHE II score and neutropenic status, 12.7 percentage points; 95.6 percent confidence interval, -0.7 to 26.0). An analysis of patients who met prespecified criteria for evaluation showed that caspofungin was superior, with a favorable response in 80.7 percent of patients, as compared with 64.9 percent of those who received amphotericin B (difference, 15.4 percentage points; 95.6 percent confidence interval, 1.1 to 29.7). Caspofungin was as effective as amphotericin B in patients who had candidemia, with a favorable response in 71.7 percent and 62.8 percent of patients, respectively (difference, 10.0 percentage points; 95.0 percent confidence interval, -4.5 to 24.5). There were significantly fewer drug-related adverse events in the caspofungin group than in the amphotericin B group. CONCLUSIONS: Caspofungin is at least as effective as amphotericin B for the treatment of invasive candidiasis and, more specifically, candidemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For invasive candidiasis, echinocandins were a great development that lowered the mortality associated with these infections, with low toxicity and few interactions with other medication (Mora-Duarte et al., 2002; Pappas et al., 2016).”
From Fungal Cell Wall: Emerging Antifungals and Drug Resistance. (2019) · cites this paper as Mora-Duarte et al., 2002
In the citing paper
“Although morbidity and mortality associated with invasive Candida infections remains high, only four major classes of antifungal agents are currently approved for systemic therapy.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“Safety and tolerability were similar between the two groups and were consistent with the reported safety profile of echinocandin class drugs. 22-26”
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Amphotericin B: 30 Years of Clinical Experience
Gallis, H. A., Drew, R. H., & Pickard, W. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.2.308 · Cited by 1,009
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Kao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A., Pfaller, M. A., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/313450 · Cited by 457
Pfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., Hollis, R. J., & The SENTRY Participant Group (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.747-751.2000 · Cited by 378
Nguyen, M. H. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430220087009 · Cited by 363
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
Bartizal, K., Gill, C. J., Abruzzo, G. K., Flattery, A. M., Kong, L., Scott, P. M., Smith, J. G., Leighton, C. E., Bouffard, A., Dropinski, J. F., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2326 · Cited by 311
Villanueva, A., Arathoon, E. G., Gotuzzo, E., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/323401 · Cited by 308
Self-citationVillanueva, A., Gotuzzo, E., Arathoon, E. G., Noriega, L. M., Kartsonis, N. A., Lupinacci, R. J., Smietana, J. M., DiNubile, M. J., & Sable, C. A. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01191-9 · Cited by 292
Self-citation
Research works printed but not linked: 4
- Bodey GP. Hematogenous and major organ candidiasis. In: Bodey GP, ed. Candidiasis: pathogenesis, diagnosis, and treatment. 2nd ed. New York: Raven Press, 1992:279-329.
- Yamamura DL, 1999, CMAJ, 160, 493
- Bachman SP, Pera S, Kirkpatrick WR, Patterson TF, Lopez-Ribot JL. In vitro activity of Cancidas (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17–20, 2000. Washington, D.C.: American Society for Microbiology, 2000:352. abstract.
- Nucci M, Santos LM, Ferradosa AS, Colombo AL. Epidemiology of candidemia due to C. parapsilosis in tertiary care hospitals in Brazil. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16–19, 2001. Washington, D.C.: American Society for Microbiology, 2001:393. abstract.
Cited by
Items 801–900 of 1,000
New Insights Regarding Yeast Survival following Exposure to Liposomal Amphotericin B
Teixeira‐Santos, R., Ricardo, E., Guerreiro, S. G., Costa‐de‐Oliveira, S., Rodrigues, A. G., & Pina‐Vaz, C. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00575-15 · Cited by 13
New antifungal agents for the treatment of candidaemia
Muñóz, P., Guinea, J., Rojas, L., & Bouza, E. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.11.007 · Cited by 14
Chastain, D. B., White, B. P., Tu, P. J., Chan, S., Jackson, B., Kubbs, K. A., Bandali, A., McDougal, S., Henao‐Martínez, A. F., & Cluck, D. B. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231175201 · Cited by 11
In vitro synergistic effects of metergoline and antifungal agents against Candida krusei
Kang, K., Wong, K. S., Seneviratne, C. J., Samaranayake, L. P., Fong, W., & Tsang, P. W. (2009) · Mycoses · doi:10.1111/j.1439-0507.2009.01747.x · Cited by 13
Advances in systemic antifungal therapy
Stevens, D. A. (2012) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2011.09.018 · Cited by 12
Hampered by historical paradigms – echinocandins and the treatment of Candida endocarditis
Gardiner, B. J., Slavin, M. A., Korman, T. M., & Stuart, R. L. (2013) · Mycoses · doi:10.1111/myc.12154 · Cited by 10
Busemann, C., Jülich, A., Buchhold, B., Schmidt, V., Schneidewind, L., Pink, D., Schmidt, C. A., Neumann, T., & Krüger, W. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2446-y · Cited by 10
Santos, C. A. Q., Rhee, Y., Czapka, M. T., Kazi, A. S., & Proia, L. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030865 · Cited by 12
Tang, B. H. E., Bay, J. W., Yeong, F. M., & Samuel, M. (2023) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2023.101362 · Cited by 13
Invasive Pilzinfektionen bei Patienten nach Lebertransplantation
Fischer, L., & Sterneck, M. R. (2005) · Mycoses · doi:10.1111/j.1439-0507.2005.01107.x · Cited by 10
Dunyach, C., Drakulovski, P., Bertout, S., Jouvert, S., Reynes, J., & Mallié, M. (2010) · Mycoses · doi:10.1111/j.1439-0507.2009.01834.x · Cited by 12
Economic Evaluation of Voriconazole for the Treatment of Candidemia in Canadian Adults
Rotstein, C., Cragin, L. S., Laverdière, M., Garber, G. E., Bow, E. J., Scalera, A., Roberts, C. S., Sorenson, S. V., & Panel, T. C. E. (2008) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2008/161835 · Cited by 11
Self-citationAnimal Models In Mycology: What Have We Learned Over The Past 30 Years
Kirkpatrick, W. R., Wiederhold, N. P., Najvar, L. K., & Patterson, T. F. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0126-6 · Cited by 11
Assessment of the In Vitro Kinetic Activity of Caspofungin against Candida glabrata
Nagappan, V., Boikov, D. A., & Vázquez, J. A. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01339-08 · Cited by 11
Nett, J. E., & Andes, D. R. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch22 · Cited by 11
DiNubile, M. J., Strohmaier, K. M., Lupinacci, R. J., Meibohm, A. R., Sable, C. A., & Kartsonis, N. A. (2008) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-008-0486-6 · Cited by 10
Self-citationPrise en charge des infections systémiques à Candida spp.
Taieb, F., Mechai, F., Lefort, A., Lanternier, F., Bougnoux, M., & Lortholary, O. (2010) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2010.08.019 · Cited by 15
Koldehoff, M., & Zakrzewski, J. L. (2005) · American Journal of Hematology · doi:10.1002/ajh.20361 · Cited by 10
Kontny, U., Walsh, T. J., Rössler, J. K., Uhl, M., & Niemeyer, C. M. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20751 · Cited by 10
Neonatal candidiasis: prophylaxis and treatment
Tiffany, K. F., Smith, P. B., & Benjamin, D. K. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.10.1647 · Cited by 11
Selection criteria for antifungals: the right patients and the right reasons
CHANDRASEKAR, P. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.03.014 · Cited by 12
The echinocandin caspofungin impairs the innate immune mechanism against Candida parapsilosis
Asbeck, E. C. V., Hoepelman, A. I. M., Scharringa, J., & Verhoef, J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.06.013 · Cited by 10
Tünger, Ö., Bayram, H., Değerli, K., Dinç, G., & Cetin, B. C. (2008) · Saudi Medical Journal · doi:10.15537/1658-3175.4332 · Cited by 12
Chen, Y., Kumar, R. N., Feng, Y.-H., Ho, C.-H., You, J.-Y., Liao, C.-C., Tseng, C.-H., Mavros, P., Gerth, W. C., & Chen, Y.-C. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl107 · Cited by 11
Trends in der chirurgischen Intensivmedizin
Schneider, C. P., Wolf, H., Küchenhoff, H., Jauch, K.-W., & Hartl, W. H. (2006) · Der Chirurg · doi:10.1007/s00104-006-1204-5 · Cited by 10
Utility of Antifungal Susceptibility Testing and Clinical Correlations
Diekema, D. J., & Pfaller, M. A. (2011) · Humana Press eBooks · doi:10.1007/978-1-59745-134-5_8 · Cited by 10
Use of antifungal drugs in hematology
Nucci, M. (2012) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.5581/1516-8484.20120095 · Cited by 10
Actualización en terapia antifúngica: nuevos fármacos e indicaciones
Fortün, J. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(11)70042-8 · Cited by 17
Influence of Serum and Albumin on Echinocandin In Vitro Potency and Pharmacodynamics
Nasar, A., Ryan, L., Frei, C. R., Cota, J. M., & Wiederhold, N. P. (2013) · Current Fungal Infection Reports · doi:10.1007/s12281-013-0136-z · Cited by 11
Dreyfuss, D., Ricard, J.-D., & Gaudry, S. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.187.6.661 · Cited by 9
Motloch, L. J., Rottlaender, D., Darabi, T., Joost, I., Erdmann, E., & Hoppe, U. C. (2011) · Europe PMC (PubMed Central) · Cited by 9
When and How to Cover for Fungal Infections in Patients with Severe Sepsis and Septic Shock
Allou, N., Allyn, J., & Montravers, P. (2011) · Current Infectious Disease Reports · doi:10.1007/s11908-011-0204-x · Cited by 10
Caspofungin therapy in immunocompromised children and neonates
Somer, A., Törün, S. H., & Salman, N. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.4 · Cited by 9
Treatment strategies for central venous catheter infections
Sabatier, C., Ferrer, R., & Vallés, J. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903133819 · Cited by 10
Actividad antifúngica in vitro de la micafungina
Quindós, G., Eraso, E., Carrillo‐Muñoz, A. J., Cantón, E., & Pemán, J. (2009) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(09)70006-3 · Cited by 9
Empiric Antifungal Therapy in Patients with Febrile Neutropenia
Ferrara, J. J., MacDougall, C., & Gallagher, J. C. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.4.369 · Cited by 10
Clinical indications for newer antifungal agents
Murphy, N. N., & Pile, J. C. (2009) · Journal of Hospital Medicine · doi:10.1002/jhm.412 · Cited by 9
Knowledge gaps in candidaemia/invasive candidiasis in haematological cancer patients
Colombo, A. L., Agnelli, C., & Kontoyiannis, D. P. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa446 · Cited by 10
Self-citationCháves, F., Garnacho‐Montero, J., del Pozo, J. L., Bouza, E., Capdevila, J. A., de Cueto, M., Domínguez, M. Á., Esteban, J., Fernández‐Hidalgo, N., Sampedro, M. F., et al. (2018) · Medicina Intensiva (English Edition) · doi:10.1016/j.medine.2017.09.001 · Cited by 15
Diagnostik und Therapie invasiver Pilzinfektionen auf der Intensivstation
Koch, S., Haefner, H., Huenger, F., Haase, G., Wildberger, J. E., & Lemmen, S. (2005) · Der Anaesthesist · doi:10.1007/s00101-005-0919-x · Cited by 12
Hayes‐Lattin, B., & Maziarz, R. T. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190310001625719 · Cited by 12
Posaconazole Activity against Candida glabrata after Exposure to Caspofungin or Amphotericin B
Spreghini, E., Maida, C. M., Milici, M. E., Scalise, G., & Barchiesi, F. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01447-07 · Cited by 9
Does One Voriconazole Breakpoint Suit All Candida Species?
Arendrup, M. C., Denning, D. W., Pfaller, M. A., Diekema, D. J., & Rex, J. H. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00412-07 · Cited by 12
Utilidad clínica de la micafungina en el tratamiento de las candidiasis invasoras en el neonato
Infante-López, M. E., & Rojo‐Conejo, P. (2009) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(09)70009-9 · Cited by 8
Kazachstania slooffiae: An unexpected journey to a human pleural sample
Mercier, V., Desnos‐Ollivier, M., Lamy, A., Mahul, M., & Sasso, M. (2020) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2020.101109 · Cited by 8
Population Pharmacokinetics of Caspofungin and Dose Simulations in Heart Transplant Recipients
Wu, Z., Lan, J., Wang, X., Wu, Y., Yao, F., Wang, Y., Zhao, B., Wang, Y., Chen, J., & Chen, C. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02249-21 · Cited by 8
Lee, S.-C., Lee, C., Shih, H.-J., Huang, S.-H., Chiou, M., & See, L. (2013) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2013.09.006 · Cited by 8
Invasive fungal disease: better survival through early diagnosis and therapeutic intervention
Maschmeyer, G. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.11 · Cited by 9
Recomendações no manejo das complicações infecciosas no transplante de células-tronco hematopoéticas
Garnica, M., Machado, C. M., Cappellano, P., Carvalho, V. V. H., Nicolato, A., da Cunha, C. A., & Nucci, M. (2010) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1590/s1516-84842010005000026 · Cited by 18
Sampaio, P., & Pais, C. (2014) · Current Clinical Microbiology Reports · doi:10.1007/s40588-014-0002-y · Cited by 62
Schwartz, I. S., & Wiederhold, N. P. (2017) · Current Fungal Infection Reports · doi:10.1007/s12281-017-0287-4 · Cited by 8
Mandibular osteomyelitis associated with candida albicans in marijuana and heroin abusers
Attie, M. D., Anderson, I., & Portnof, J. E. (2018) · Annals of Maxillofacial Surgery · doi:10.4103/ams.ams_83_18 · Cited by 10
Soni, N., & Wagstaff, A. (2005) · Current Anaesthesia and Critical Care · doi:10.1016/j.cacc.2005.11.010 · Cited by 13
Nouveaux antifongiques : voriconazole et caspofungine
Dupont, B. (2003) · Archives de Pédiatrie · doi:10.1016/s0929-693x(03)90043-1 · Cited by 10
Störzinger, D., Lichtenstern, C., Swoboda, S., Weigand, M. A., & Hoppe‐Tichy, T. (2008) · Mycoses · doi:10.1111/j.1439-0507.2008.01573.x · Cited by 8
Treatment Options for Invasive Fungal Infections
Ashley, E. S. D. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.6part2.55s · Cited by 9
Sequential Therapy with Caspofungin and Fluconazole for Candida albicans Infection
Barchiesi, F., Spreghini, E., Baldassarri, I., Marigliano, A., Arzeni, D., Giannini, D., & Scalise, G. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.4056-4058.2004 · Cited by 8
Actividad antifúngica in vitro de la anidulafungina
Quindós, G., & Eraso, E. (2008) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(08)70025-1 · Cited by 8
Greene, J. N. (2004) · CRC Press eBooks · doi:10.1201/b14158 · Cited by 8
Trends in der chirurgischen Intensivmedizin
Schneider, C. P., Wolf, H., Küchenhoff, H., Jauch, K. ‐., & Hartl, W. H. (2006) · Der Chirurg · doi:10.1007/s00104-006-1242-z · Cited by 8
Reboli, A. C. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu160 · Cited by 8
Li, Z., Cui, Z., Xie, D., Zou, F., & Zhu, C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1632488 · Cited by 9
Clinical Insights: Antimicrobial Therapy for Infectious Uveitis
Leong, E., Cifuentes‐González, C., W., J. H. Y., Samy, R. P., Khairallah, M., Rojas-Carabali, W. A., Putera, I., de‐la‐Torre, A., & Agrawal, R. V. (2024) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2024.2345848 · Cited by 7
Mechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2015) · ASM Press eBooks · doi:10.1128/9781555817381.ch130 · Cited by 9
Altıntaş, A., Ayyildiz, O. M., Işıkdoğan, A., Atay, E., & Ma, K. (2006) · Saudi Medical Journal · doi:10.15537/1658-3175.3602 · Cited by 7
Dib, R. W., Hachem, R. Y., Chaftari, A., & RAAD, I. I. (2018) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2018.028 · Cited by 8
Clinical Syndromes: Candida and Candidosis
Ruhnke, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-92300-0_4 · Cited by 8
Caspofungin for the treatment of candidaemia in patients with haematological malignancies
Pagano, L., Fianchi, L., Fanci, R., Candoni, A., Caira, M., Posteraro, B., Morselli, M., Valentini, C. G., Farina, G., Mitra, M. E., et al. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02832.x · Cited by 7
Yuan, X., Wang, R., Bai, C.-Q., Song, X., & Liu, Y.-N. (2012) · Die Pharmazie · doi:10.31083/ph.2012.1793 · Cited by 8
Effect of fluid loading during hypovolaemic shock on caspofungin pharmacokinetic parameters in pig
Roch, A., Woloch, C., Blayac, D., Solas, C., Quaranta, S., Mardelle, V., Castanier, M., Papazian, L., & Sampol-Manos, E. (2011) · Critical Care · doi:10.1186/cc10455 · Cited by 7
Pharmacotherapy of Candida Infections with Echinocandins
Espinel-Ingroff, A. V., Canton, E., Martín‐Mazuelos, E., & Pemán, J. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2311 · Cited by 7
Management of Multidrug Resistant Infections in Lung Transplant Recipients with Cystic Fibrosis
Vazirani, J., Crowhurst, T., Morrissey, C. O., & Snell, G. I. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s301153 · Cited by 7
Candida Colonization Index in the Management of Critically III Patients
Eggimann, P., & Pittet, D. (2006) · Yearbook of intensive care and emergency medicine · doi:10.1007/3-540-33396-7_56 · Cited by 9
Schneeweiß, S., Carver, P. L., Datta, K., Galar, A., Johnson, M. D., Letourneau, A. R., Marty, F. M., Nagel, J. L., Najdzinowicz, M., Saul, M. I., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz396 · Cited by 8
Therapeutic armamentarium against systemic fungal infections
Cisneros, J. M., & Cordero, E. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01606.x · Cited by 8
Critical overview of clinical guidelines relating to invasive fungal infections
Sá, M. B., & Zaragoza, R. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(08)70018-9 · Cited by 7
Therapie schwerer Pilzinfektionen
Battegay, M., & Flckiger, U. (2003) · Der Internist · doi:10.1007/s00108-003-1065-7 · Cited by 9
Pharmacological advances in the treatment of invasive candidiasis
Deck, D. H., & Guglielmo, B. J. (2006) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.4.1.137 · Cited by 8
Los aspectos epidemiológicos cambiantes de la candidemia y sus implicaciones clinicoterapéuticas
Salavert, M., Ramos, I. J., & Pemán, J. (2006) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1157/13094277 · Cited by 18
Schell, W. A., Foulks, G. N., & Perfect, J. R. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-0016-7.50018-7 · Cited by 8
Self-citationRecent Advances of Serodiagnosis for Systemic Fungal Infections
Yoshida, K. (2006) · Nippon Ishinkin Gakkai Zasshi · doi:10.3314/jjmm.47.135 · Cited by 7
Eichhorn, M., Wolf, H., Küchenhoff, H., Joka, M., Jauch, K. ‐., & Hartl, W. H. (2007) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-007-0305-5 · Cited by 8
Impact of real-time fungal susceptibility on clinical practices
Magiorakos, A.-P., & Hadley, S. (2004) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200412000-00002 · Cited by 7
Cisneros, J. M., Neth, O., & Pachón, J. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis524 · Cited by 7
Clinical impact of fluconazole-resistant Candida parapsilosis : a narrative review
Bartalucci, C., Vena, A., Giacobbe, D. R., & Bassetti, M. (2025) · Future Microbiology · doi:10.1080/17460913.2025.2544443 · Cited by 9
Updated guidelines for managing fungal diseases in hematology patients
Hicheri, Y., Toma, A., Maury, S., Pautas, C., Mallek, H., & Cordonnier, C. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.85 · Cited by 10
Nuevos antifúngicos: Las equinocandinas
Alexis Diomedi, P. (2004) · Revista chilena de infectología · doi:10.4067/s0716-10182004000200001 · Cited by 15
Antifungal Therapy in Eye Infections: New Drugs, New Trends
Joseph, J., & Sharma, S. (2016) · Springer eBooks · doi:10.1007/978-81-322-2782-3_9 · Cited by 8
Kubota, K., Soma, K., Uehara, M., Inaba, T., Saito, A., Takeda, N., Hatano, M., Morita, H., Inuzuka, R., Hirata, Y., et al. (2018) · International Heart Journal · doi:10.1536/ihj.17-314 · Cited by 6
A Case of Candidemia after Long-term Presence of Urethral Foreign Bodies
Nagata, J., Kawasaki, T., Iesato, K., Sugiura, T., Yamauchi, K., Tsuyusaki, J., Fujimura, M., Kuroda, F., Mikami, K., Dudek, S. M., et al. (2021) · IDCases · doi:10.1016/j.idcr.2021.e01176 · Cited by 7
Infection in the Patient With Cancer
Freifeld, A. G., & Kaul, D. R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00034-7 · Cited by 11
Aguiar, T. K. B., Costa, A. C. M., Neto, N. A. S., Brito, D. M. D. S., Freitas, C. D. T., Neto, J. M. D. M., Mesquita, F. P., & Souza, P. F. N. (2024) · Future Microbiology · doi:10.2217/fmb-2023-0236 · Cited by 7
Ochieng, P., McLigeyo, S., Amayo, E., Kayima, J. K., & Omonge, E. (2010) · East African Medical Journal · doi:10.4314/eamj.v86i9.54166 · Cited by 7
Mahboubi, M., & Kazempour, N. (2016) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2015.11.003 · Cited by 7
Antifungal and Antiviral Therapy
Ostrosky-Zeichner, L. L., & Rex, J. H. (2008) · Elsevier eBooks · doi:10.1016/b978-032304841-5.50055-8 · Cited by 6
Has the Optimal Therapy for Invasive Candidiasis Now Been Defined?
Andes, D. R. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy830 · Cited by 6
Wattier, R. L., & Steinbach, W. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-40181-4.00293-0 · Cited by 6
Caspofungin Effects on Electrocardiogram of Mice: An Evaluation of Cardiac Safety
de Paula, D. C. C., Leite, E. A., Araújo, C. M., Branquinho, R. T., Guimarães, H. N., & Grabe‐Guimarães, A. (2020) · Cardiovascular Toxicology · doi:10.1007/s12012-020-09599-x · Cited by 6
The current place of echinocandins in the treatment and prophylaxis of invasive fungal infections
Veselov, A. V. (2020) · Clinical Microbiology and Antimicrobial Chemotherapy · doi:10.36488/cmac.2020.3.197-209 · Cited by 8
Candida Infections in Solid Organ Transplantation
Barros, N., & Mansour, M. K. (2021) · Springer eBooks · doi:10.1007/978-3-030-25869-6_43 · Cited by 7
Metadata
- Authors
- Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J.
- Affiliations
- Costa Rican Department of Social Security (CR)
- University of Rochester (US)
- McMaster University (CA)
- Universidade Federal de São Paulo (BR)
- Clinica Santa Maria (CL)
- Duke University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-12-19
- Volume
- 347
- Issue
- 25
- Pages
- 2020-2029
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003661565
- Cited by
- 1,380
- References
- 31
- Citations by year
- 2026: 10 · 2025: 26 · 2024: 17 · 2023: 14 · 2022: 18 · 2021: 30 · 2020: 28 · 2019: 30 · 2018: 29 · 2017: 44 · 2016: 30 · 2015: 50 · 2014: 44 · 2013: 53 · 2012: 62
- FWCI
- 56.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- caspofungin, amphotericin B deoxycholate, invasive candidiasis, candidemia, echinocandins, antifungal therapy, treatment efficacy, drug-related adverse events, neutropenia, APACHE II score, Candida species, randomized trial comparison, length of hospital stay, cost-effectiveness
- MeSH terms
- Caspofungin, Adolescent, Adult, Aged, Aged, 80 and over, Amphotericin B, Anti-Bacterial Agents, Antifungal Agents, Candida, Candidiasis, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Neutropenia, Peptides, Peptides, Cyclic, Recurrence, Fungemia, APACHE, Echinocandins, Lipopeptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.